Endocrinology, Diabetes & Metabolism Doctors in Bangor, ME Accepting Medicare

6 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 6

Ana X Mendoza Salazar, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 900 Broadway, Bangor, ME 04401 Phone: 207-907-1187    Fax: 207-907-1189

Stephany Khalil Matta, M.D Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 905 Union St Ste 11, Bangor, ME 04401 Phone: 207-973-8423    Fax: 207-973-7424

Dr. Shazia Ahmad, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 905 Union St Ste 11, Bangor, ME 04401 Phone: 207-973-7334

Katarzyna Sadurska, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 905 Union St, Suite 11, Bangor, ME 04401 Phone: 207-973-7334    Fax: 207-973-7424

Poonam Khadka, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 900 Broadway, Bangor, ME 04401 Phone: 207-907-1187    Fax: 207-907-1189

Dr. Mark Henderson, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 900 Broadway, Bangor, ME 04401 Phone: 207-907-1187    Fax: 207-907-1189

News Archive

GM soybean oil as unhealthy as regular soybean oil, but may not cause insulin resistance

Soybean oil accounts for more than 90 percent of all the seed oil production in the United States. Genetically modified (GM) soybean oil, made from seeds of GM soybean plants, was recently introduced into the food supply on the premise that it is healthier than conventional soybean oil.

Endocrine disrupting chemicals may affect human reproductive system: Research

New research has provided the first evidence that 'gender bending' chemicals which find their way from human products into rivers and oceans can have a significant impact on the ability of fish to breed in UK Rivers.

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010.

Self-care polymers fibers recognize need for therapy

Drug-releasing textiles could, for instance, be used to treat skin wounds. Empa researchers are currently developing polymer fibers that can be equipped with drugs. The smart fibers recognize the need for therapy all by themselves and dose the active ingredients with precision and accuracy.

Read more Medical News

› Verified 9 days ago